Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated for symptomatic treatment of focal spasticity of:
- Upper limbs in adults
- Lower limbs in adults affecting the ankle joint
Please click here to see the full therapeutic indications.
CLIMB Online
Adult Spasticity
Making sense of the changing NHS and funding flows
12 minutes
Dr Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.
DYS-UK-007356
Navigating the Switch between BoNT-As: The North Staffordshire Rehabilitation Centre Experience
10 minutes
Dr Clive Bezzina shares his personal experience switching between BoNT-As within his spasticity service, and the outcomes seen for both the patients and the service.
DYS-UK-007573
Dysport® Dilution Guide
2 pages
A downloadable reference guide to reconstituting and diluting Dysport®
DYS-UK-007576
BoNT Immunogenicity: The difference between neutralising and non-neutralising antibodies
3 minutes
Understand the difference between neutralising and non-neutralising antibodies and how this difference should be considered during clinical decision-making.
DYS-UK-007538
Finding flexibility within Botulinum Toxin clinics: Using Dysport® to enable PIFU
6 Minutes
Dr Clive Bezzina discusses his experience of how Dysport® enabled his service to use a PIFU model.
DYS-UK-007577
Dysport® in clinical practice: A case study of a 75-year-old female with focal spasticity
5 minutes
Dr Clive Bezzina explains his approach to treating a 75-year-old female with focal spasticity with Dysport®.
DYS-UK-007578
Dysport® in clinical practice: A case study of a 23-year-old male with focal spasticity
9 minutes
Dr Clive Bezzina explains his approach to treating a 23-year-old male with focal spasticity with Dysport®.
DYS-UK-007579
Demystifying the Clinical Relevance of BoNT Immunogenicity
5 minutes
Learn about the difference between neutralising and non-neutralising antibodies, and factors to consider when investigating non-response to BoNT treatment
Presented by: Dr Tim Harrower
DYS-UK-007574
Flexibility with Dysport in Clinical Practice: A case study (53M with Focal Spasticity)
8 minutes
Presented by: Dr Ganesh Bavikatte
DYS-UK-007570
Ultrasound Essentials – Introduction
9 minutes
How to use ultrasound to identify muscles in the upper and lower limb, to assist the administration of Dysport® via intramuscular injection.
DYS-UK-007964
Ultrasound Essentials – Shoulder
15 minutes
How to identify muscles of the shoulder using ultrasound for injection with Dysport®.
DYS-UK-007969
Ultrasound Essentials – Elbow
12 minutes
How to identify the elbow flexor and extensor muscles using ultrasound for injection with Dysport®.
DYS-UK-007968
Ultrasound Essentials – Forearm
10 mintues
How to identify the forearm flexor and pronator muscles using ultrasound for injection with Dysport®.
DYS-UK-007966
Ultrasound Essentials – Hand
12 minutes
How to identify the muscles of the thumb and hand using ultrasound for injection with Dysport®.
DYS-UK-007965
Ultrasound Essentials – Lower Limb
18 minutes
How to identify the muscles of the posterior lower leg and foot using ultrasound for injection with Dysport®.
DYS-UK-007967
Dysport® Mechanism of Action
3 minutes
DYS-UK-007580
© IPSEN Ltd, 5th Floor The Point, 37 North Wharf Road, London, W2 1AF, United Kingdom. All rights reserved. February 2024 DYS-UK-008397
